Oxford University is partnering with a vaccine manufacturer, trial results expected in June

Author : brocardic1934
Publish Date : 2021-04-03


Oxford University is partnering with a vaccine manufacturer, trial results expected in June

'This is still a development program. We need still to demonstrate that this vaccine works in human populations,' he told BBC Radio. 'But the team ... have vaccinated several hundred people now and we hope to get some signal about whether it's working by the middle of June.'

The Oxford University research team is partnering with UK-based global biopharmaceutical company AstraZeneca to develop and manufacture this vaccine on a large scale.

'Once we get an approval by the regulators, we don't want to have to go back to the beginning and work out how we manufacture it at scale. And we also want to make sure that the rest of the world will be ready to make this vaccine at scale,' Bell said.



https://cde.instructure.com/eportfolios/196061/Home/DOWNLOAD_ALBUM_Buffering_the_Vampire_Sla__Songs_from_Season_Three_Zip_Mp3
https://cde.instructure.com/eportfolios/196059/Home/DownloadMp3_H1GHR_MUSIC__H1GHR__BLUE_TAPE_Album_Download
https://cde.instructure.com/eportfolios/196056/Home/Download_Zip__Mp3_Various_Artists__Vip_Full_Album_Download
https://cde.instructure.com/eportfolios/196058/Home/ZipDownloadMp3_Shelly_Berg_Jos_Serebri_Gershwin_Reimagined_An_A_Album_Download
https://cde.instructure.com/eportfolios/196055/Home/DOWNLOAD_ALBUM_Jorn_Van_Deynhoven__Anthems_The_Remixes_Pt_Zip_Mp3


According to the university, AstraZeneca will work with global partners on the international distribution of the vaccine, particularly working to make it available and accessible for low- and medium-income countries.

'Both partners have agreed to operate on a not-for-profit basis for the duration of the coronavirus pandemic, with only the costs of production and distribution being covered,' the university said.

'Both partners have agreed to operate on a not-for-profit basis for the duration of the coronavirus pandemic, with only the costs of production and distribution being covered,' the university said. The Oxford University research team is partnering with UK-based global biopharmaceutical company AstraZeneca to develop and manufacture this vaccine on a large scale. 'Both partners have agreed to operate on a not-for-profit basis for the duration of the coronavirus pandemic, with only the costs of production and distribution being covered,' the university said. 'Both partners have agreed to operate on a not-for-profit basis for the duration of the coronavirus pandemic, with only the costs of production and distribution being covered,' the university said. 'Both partners have agreed to operate on a not-for-profit basis for the duration of the coronavirus pandemic, with only the costs of production and distribution being covered,' the university said. 'Once we get an approval by the regulators, we don't want to have to go back to the beginning and work out how we manufacture it at scale. And we also want to make sure that the rest of the world will be ready to make this vaccine at scale,' Bell said. 'This is still a development program. We need still to demonstrate that this vaccine works in human populations,' he told BBC Radio. 'But the team ... have vaccinated several hundred people now and we hope to get some signal about whether it's working by the middle of June.' 'This is still a development program. We need still to demonstrate that this vaccine works in human populations,' he told BBC Radio. 'But the team ... have vaccinated several hundred people now and we hope to get some signal about whether it's working by the middle of June.' 'Both partners have agreed to operate on a not-for-profit basis for the duration of the coronavirus pandemic, with only the costs of production and distribution being covered,' the university said. The Oxford University research team is partnering with UK-based global biopharmaceutical company AstraZeneca to develop and manufacture this vaccine on a large scale. According to the university, AstraZeneca will work with global partners on the international distribution of the vaccine, particularly working to make it available and accessible for low- and medium-income countries. 'Once we get an approval by the regulators, we don't want to have to go back to the beginning and work out how we manufacture it at scale. And we also want to make sure that the rest of the world will be ready to make this vaccine at scale,' Bell said. The Oxford University research team is partnering with UK-based global biopharmaceutical company AstraZeneca to develop and manufacture this vaccine on a large scale. The Oxford University research team is partnering with UK-based global biopharmaceutical company AstraZeneca to develop and manufacture this vaccine on a large scale. 'Both partners have agreed to operate on a not-for-profit basis for the duration of the coronavirus pandemic, with only the costs of production and distribution being covered,' the university said. 'This is still a development program. We need still to demonstrate that this vaccine works in human populations,' he told BBC Radio. 'But the team ... have vaccinated several hundred people now and we hope to get some signal about whether it's working by the middle of June.' 'Both partners have agreed to operate on a not-for-profit basis for the duration of the coronavirus pandemic, with only the costs of production and distribution being covered,' the university said. 'Once we get an approval by the regulators, we don't want to have to go back to the beginning and work out how we manufacture it at scale. And we also want to make sure that the rest of the world will be ready to make this vaccine at scale,' Bell said. 'Both partners have agreed to operate on a not-for-profit basis for the duration of the coronavirus pandemic, with only the costs of production and distribution being covered,' the university said. 'Both partners have agreed to operate on a not-for-profit basis for the duration of the coronavirus pandemic, with only the costs of production and distribution being covered,' the university said.

#newsupdatenow



Category :accounting

How AS Monaco toppled big spenders PSG to win Ligue 1

How AS Monaco toppled big spenders PSG to win Ligue 1

- A 2-0 win against Saint-Étienne, courtesy of a cool finish from Kylian Mbappé and a last-minute goal


Greece saves Europe: How press reacted to the vote

Greece saves Europe: How press reacted to the vote

- The election in Greece of a pro-bailout party induced a huge sigh of relief well beyond Athens and p


Glass, silence and no offices -- What the super rich want on a superyacht

Glass, silence and no offices -- What the super rich want on a superyacht

- When millionaires go on vacations on their superyachts, theres one thing some crave more than anyth


Hong Kong Sevens: Sonny Bill Williams makes young fans dream come true

Hong Kong Sevens: Sonny Bill Williams makes young fans dream come true

- After handing out his Rugby World Cup winners medal to a starstruck fan last October, Sonny Bill Wi